Merck canada announces conditional approval of keytruda (pembrolizumab) for melanoma treatment

"Many of us at Merck Canada are thrilled with KEYTRUDA being offered in Canada to treat advanced melanoma, because it provides new therapy to patients facing this difficult-to-treat cancer," stated Chirfi Guindo, Md, Merck Canada Corporation. "This latest product embodies Merck’s unwavering dedication to be the main thing on scientific discovery and innovation to assist …
West Rules Corp